Cubist, Hospira infectious news

The U.S. District Court for the District of Delaware ruled that Cubist’s antibiotic Cubicin daptomycin has patent exclusivity until June 15, 2016.

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE